Home > > > > Report Detail

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Publisher Name :
Date: 14-Sep-2022
No. of pages: 121
Inquire Before Buying

A biomarker is, according to the US National Institutes of Health, "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention."

Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.

Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.

We can discriminate four main types of molecular biomarkers:

• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.

• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.

• Proteomic biomarkers: Base on the analysis of the protein profiles.

• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).

Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.

Highlights

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market is projected to reach US$ 29810 million by 2028 from an estimated US$ 22500 million in 2022, at a CAGR of 4.8% during 2023 and 2028.

The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers in Therapeutic and Diagnostic Applications.

The Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

- Roche

- Dako (Agilent Technologies)

- Merck

- BD

- Abbott

- Genesys Biolabs (20/20GeneSystems)

- Affymetrix

- Agendia

- ALMAC

- Arrayit

- Biocartic

- BG Medicine

- KEGG EXPRESSION Database

- Thermo Fisher

- BGI

Product Type Insights

Global markets are presented by Commercializing Biomarkers in Therapeutic and Diagnostic Applications type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Commercializing Biomarkers in Therapeutic and Diagnostic Applications are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Commercializing Biomarkers in Therapeutic and Diagnostic Applications Segment by Type

- Consumables

- Services

- Software

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).

This report also outlines the market trends of each segment and consumer behaviors impacting the Commercializing Biomarkers in Therapeutic and Diagnostic Applications market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Commercializing Biomarkers in Therapeutic and Diagnostic Applications market.

Commercializing Biomarkers in Therapeutic and Diagnostic Applications Segment by Application

- Oncology

- Cardiology

- Neurology

- Other

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue of each region and country for the period 2017-2028.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- - Nordic Countries

- - Benelux

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Southeast Asia

- - Australia

- - Rest of Asia-Pacific

- Latin America

- - Mexico

- - Brazil

- - Argentina

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of Middle East & Africa

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Commercializing Biomarkers in Therapeutic and Diagnostic Applications market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Commercializing Biomarkers in Therapeutic and Diagnostic Applications and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Commercializing Biomarkers in Therapeutic and Diagnostic Applications industry.

This report helps stakeholders to gain insights into which regions to target globally.

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Commercializing Biomarkers in Therapeutic and Diagnostic Applications.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2022-2028

Table of Contents
1 Study Coverage
1.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Introduction
1.2 Market by Type
1.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 Consumables
1.2.3 Services
1.2.4 Software
1.3 Market by Application
1.3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Application (2017 VS 2021 VS 2028)
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Estimates and Forecasts
2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region: 2022 Versus 2028
2.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Region: 2017-2022
2.2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Forecast by Region (2023-2028)
2.2.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Region (2017-2028)
3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Company
3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Company (2017-2022)
3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Company (2017-2022)
3.3 Competitive Landscape
3.3.1 Key Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies around the World: Ranking by Revenue
3.3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio (CR5 and HHI) & (2017-2022)
3.3.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Headquarters & Product Type
3.4.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Headquarters
3.4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Product & Service
3.4.3 Date of International Companies Enter into Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market
3.5 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Roche
4.1.1 Roche Corporation Information
4.1.2 Roche Description, Business Overview
4.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.1.4 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.1.5 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.1.6 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.1.7 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.1.8 Roche Recent Developments
4.2 Dako (Agilent Technologies)
4.2.1 Dako (Agilent Technologies) Corporation Information
4.2.2 Dako (Agilent Technologies) Description, Business Overview
4.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.2.4 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.2.5 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.2.6 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.2.7 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.2.8 Dako (Agilent Technologies) Recent Developments
4.3 Merck
4.3.1 Merck Corporation Information
4.3.2 Merck Description, Business Overview
4.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.3.4 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.3.5 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.3.6 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.3.7 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.3.8 Merck Recent Developments
4.4 BD
4.4.1 BD Corporation Information
4.4.2 BD Description, Business Overview
4.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.4.4 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.4.5 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.4.6 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.4.7 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.4.8 BD Recent Developments
4.5 Abbott
4.5.1 Abbott Corporation Information
4.5.2 Abbott Description, Business Overview
4.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.5.4 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.5.5 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.5.6 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.5.7 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.5.8 Abbott Recent Developments
4.6 Genesys Biolabs (20/20GeneSystems)
4.6.1 Genesys Biolabs (20/20GeneSystems) Corporation Information
4.6.2 Genesys Biolabs (20/20GeneSystems) Description, Business Overview
4.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.6.4 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.6.5 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.6.6 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.6.7 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.6.8 Genesys Biolabs (20/20GeneSystems) Recent Development
4.7 Affymetrix
4.7.1 Affymetrix Corporation Information
4.7.2 Affymetrix Description, Business Overview
4.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.7.4 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.7.5 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.7.6 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.7.7 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.7.8 Affymetrix Recent Development
4.8 Agendia
4.8.1 Agendia Corporation Information
4.8.2 Agendia Description, Business Overview
4.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.8.4 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.8.5 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.8.6 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.8.7 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.8.8 Agendia Recent Development
4.9 ALMAC
4.9.1 ALMAC Corporation Information
4.9.2 ALMAC Description, Business Overview
4.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.9.4 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.9.5 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.9.6 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.9.7 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.9.8 ALMAC Recent Development
4.10 Arrayit
4.10.1 Arrayit Corporation Information
4.10.2 Arrayit Description, Business Overview
4.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.10.4 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.10.5 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.10.6 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.10.7 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.10.8 Arrayit Recent Development
4.11 Biocartic
4.11.1 Biocartic Corporation Information
4.11.2 Biocartic Description, Business Overview
4.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.11.4 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.11.5 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.11.6 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.11.7 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.11.8 Biocartic Recent Development
4.12 BG Medicine
4.12.1 BG Medicine Corporation Information
4.12.2 BG Medicine Description, Business Overview
4.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.12.4 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.12.5 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.12.6 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.12.7 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.12.8 BG Medicine Recent Development
4.13 KEGG EXPRESSION Database
4.13.1 KEGG EXPRESSION Database Corporation Information
4.13.2 KEGG EXPRESSION Database Description, Business Overview
4.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.13.4 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.13.5 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.13.6 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.13.7 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.13.8 KEGG EXPRESSION Database Recent Development
4.14 Thermo Fisher
4.14.1 Thermo Fisher Corporation Information
4.14.2 Thermo Fisher Description, Business Overview
4.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.14.4 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.14.5 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.14.6 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.14.7 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.14.8 Thermo Fisher Recent Development
4.15 BGI
4.15.1 BGI Corporation Information
4.15.2 BGI Description, Business Overview
4.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.15.4 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2017-2022)
4.15.5 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2021
4.15.6 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2021
4.15.7 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2021
4.15.8 BGI Recent Development
5 Breakdown Data by Type
5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2017-2022)
5.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Forecast by Type (2023-2028)
5.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Marke Share by Type (2017-2028)
6 Breakdown Data by Application
6.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2017-2022)
6.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Forecast by Application (2023-2028)
6.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Application (2017-2028)
7 North America
7.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth 2017-2028
7.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Facts & Figures by Country (2017-2028)
7.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2017-2022)
7.4 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2017-2022)
8 Asia-Pacific
8.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth 2017-2028
8.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Facts & Figures by Region (2017-2028)
8.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2017-2022)
8.4 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2017-2022)
9 Europe
9.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth 2017-2028
9.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Facts & Figures by Country (2017-2028)
9.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2017-2022)
9.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2017-2022)
10 Latin America
10.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth 2017-2028
10.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Facts & Figures by Country (2017-2028)
10.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2017-2022)
10.4 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2017-2022)
11 Middle East and Africa
11.1 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth 2017-2028
11.2 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Facts & Figures by Country (2017-2028)
11.3 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2017-2022)
11.4 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2017-2022)
12 Supply Chain and Sales Channel Analysis
12.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Supply Chain Analysis
12.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Key Raw Materials and Upstream Suppliers
12.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Clients Analysis
12.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Channel and Sales Model Analysis
12.4.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Distributors
13 Market Dynamics
13.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Trends
13.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers
13.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
13.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Major Companies of Consumables
Table 3. Major Companies of Services
Table 4. Major Companies of Software
Table 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (US$ Million): 2022 VS 2028
Table 7. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Region (2017-2022) & (US$ Million)
Table 8. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 9. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Company (2017-2022) & (US$ Million)
Table 10. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Company (2017-2022)
Table 11. Ranking of Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue (US$ Million) in 2021
Table 12. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Market Concentration Ratio (CR5 and HHI) & (2017-2022)
Table 13. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications as of 2021)
Table 14. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Headquarters
Table 15. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Product & Service
Table 16. Date of International Companies Enter into Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market
Table 17. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Mergers & Acquisitions, Expansion Plans
Table 18. Roche Corporation Information
Table 19. Roche Description and Business Overview
Table 20. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 21. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 22. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product in 2021
Table 23. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2021
Table 24. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Geographic Area in 2021
Table 25. Roche Recent Development
Table 26. Dako (Agilent Technologies) Corporation Information
Table 27. Dako (Agilent Technologies) Description and Business Overview
Table 28. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 29. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 30. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product in 2021
Table 31. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2021
Table 32. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Geographic Area in 2021
Table 33. Dako (Agilent Technologies) Recent Development
Table 34. Merck Corporation Information
Table 35. Merck Description and Business Overview
Table 36. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 37. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 38. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product in 2021
Table 39. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2021
Table 40. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Geographic Area in 2021
Table 41. Merck Recent Development
Table 42. BD Corporation Information
Table 43. BD Description and Business Overview
Table 44. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 45. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 46. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product in 2021
Table 47. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2021
Table 48. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Geographic Area in 2021
Table 49. BD Recent Development
Table 50. Abbott Corporation Information
Table 51. Abbott Description and Business Overview
Table 52. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 53. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 54. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product in 2021
Table 55. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2021
Table 56. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Geographic Area in 2021
Table 57. Abbott Recent Development
Table 58. Genesys Biolabs (20/20GeneSystems) Corporation Information
Table 59. Genesys Biolabs (20/20GeneSystems) Description and Business Overview
Table 60. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 61. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 62. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product in 2021
Table 63. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2021
Table 64. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Geographic Area in 2021
Table 65. Affymetrix Corporation Information
Table 66. Affymetrix Description and Business Overview
Table 67. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 68. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 69. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product in 2021
Table 70. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2021
Table 71. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Geographic Area in 2021
Table 72. Agendia Corporation Information
Table 73. Agendia Description and Business Overview
Table 74. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 75. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 76. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product in 2021
Table 77. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2021
Table 78. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Geographic Area in 2021
Table 79. ALMAC Corporation Information
Table 80. ALMAC Description and Business Overview
Table 81. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 82. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 83. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product in 2021
Table 84. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2021
Table 85. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Geographic Area in 2021
Table 86. Arrayit Corporation Information
Table 87. Arrayit Description and Business Overview
Table 88. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 89. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 90. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Product in 2021
Table 91. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application in 2021
Table 92. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Proportion of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Geographic Area in 2021
Table 93. Biocartic Corporation Information
Table 94. Biocartic Description and Business Overview
Table 95. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) and Gross Margin (2017-2022)
Table 96. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 97. Biocartic Commercializing Biomarkers in
  • Global Biomarkers Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94
    According to our LPI (LP Information) latest study, the global Biomarkers market size was valued at US$ 61570 million in 2023. With growing demand in downstream market, the Biomarkers is forecast to a readjusted size of US$ 165240 million by 2030 with a CAGR of 15.1% during review period. The research report highlights the growth potential of the global Biomarkers market. Biomarkers are expected to show stable growth in the future market. However, product differentiation, reducing costs,......
  • Global Biomarker (Medicine) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 114
    Market Overview of Global Biomarker (Medicine) market: According to our latest research, the global Biomarker (Medicine) market looks promising in the next 5 years. As of 2022, the global Biomarker (Medicine) market was estimated at USD 54332.95 million, and it's anticipated to reach USD 82760.29 million in 2028, with a CAGR of 7.27% during the forecast years. Biomarkers (short for biological markers) are biological measures of a biological state. By definition, a biomarker i......
  • Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size was valued at US$ 20920 million in 2023. With growing demand in downstream market, the Commercializing Biomarkers in Therapeutic and Diagnostic Applications is forecast to a readjusted size of US$ 29400 million by 2030 with a CAGR of 5.0% during review period. The research report highlights the growth potential of the global Commercializing Biom......
  • Global Biomarkers Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 100
    Market Overview of Global Biomarkers market: According to our latest research, the global Biomarkers market looks promising in the next 5 years. As of 2022, the global Biomarkers market was estimated at USD 76755.97 million, and it's anticipated to reach USD 184776.75 million in 2028, with a CAGR of 15.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Biomarkers market, with a......
  • Global Biomarker Technology Market Research Report 2023
    Published: 01-Dec-2023        Price: US 2900 Onwards        Pages: 86
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biomarker Technology market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Abbott Laboratories - Quanterix - Bio-Rad Laboratories - Epigenomics - Agilent Technologies - Johnson & Johnson - Qiagen - Roche Ho......
  • Global Renal Biomarkers Market Research Report 2023
    Published: 01-Dec-2023        Price: US 2900 Onwards        Pages: 99
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Renal Biomarkers market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Abbott Diagnostics - F. Hoffmann-La Roche - Beckman Coulter - Siemens Healthcare Diagnostics - Thermo Fisher Scientific - Astute Medical - Bio......
  • Global Central Nervous System (CNS) Biomarkers Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 114
    Market Overview of Global Central Nervous System (CNS) Biomarkers market: According to our latest research, the global Central Nervous System (CNS) Biomarkers market looks promising in the next 5 years. As of 2022, the global Central Nervous System (CNS) Biomarkers market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. An overview of the global market for central nervous system (CNS) biomarke......
  • Global Cancer Biomarker Market Research Report 2023
    Published: 13-Nov-2023        Price: US 2900 Onwards        Pages: 109
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Cancer Biomarker market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Thermo Fisher Scientific - Bio-Rad Laboratories - Roche Diagnostics - Qiagen - Illumina - GE Healthcare - Agilent Technologies - Biomér......
  • Biomarker Collaboration and Licensing Deals 2016-2023
    Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300
    Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of biomarker deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter biomarker deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercializ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs